News Article | May 10, 2017
OCALA, Fla.--(BUSINESS WIRE)--REV Group (NYSE: REVG), a $2+ billion manufacturer of industry-leading specialty vehicle brands and leading provider of parts and services, is pleased to announce Premier Fire Apparatus, as an E-ONE brand dealership in targeted regions of New York. Premier Fire Apparatus will serve as the exclusive dealership of E-ONE trucks for both sales and service for the New York counties of Albany, Columbia, Delaware, Dutchess, Fulton, Greene, Montgomery, Orange, Otsego, Putnam, Rensselaer, Rockland, Saratoga, Schenectady, Schoharie, Sullivan, Ulster, and Westchester. This spring, Premier Fire Apparatus Owner, Ken Finke, acquired a former E-ONE dealership. Ken brings over 40 years of fire industry experience, and has served as Fire District Commissioner, Fire Department Chief, and fire fighter. He is an active member of the Cornell Hook & Ladder Fire Company in New Baltimore and has served on several truck purchasing committees. “I know how important it is to have the right tools for the job, including the right piece of equipment that is designed to allow fire fighters to do their job safely,” Ken Finke says. “As an E-ONE Dealer, I am fully committed with an emphasis on customer service. " "We are pleased to have Premier Fire Apparatus on board as an E-ONE dealer serving our New York Customers,” says E-ONE Key Account Manager Alan Hollister. “Ken's business acumen as well as his history of success will make him a valued asset to the fire service industry. With the addition of Premier Fire, the E-ONE dealer network continues to grow, providing further capabilities and support for our customers." Premier Fire Apparatus is located at 1564 Route 9G Hyde Park, NY 12538. To contact Premier, email email@example.com or call 845-229-6041. REV (NYSE: REVG) is a leading designer, manufacturer and distributor of specialty vehicles and related aftermarket parts and services. We serve a diversified customer base primarily in the United States through three segments: Fire & Emergency, Commercial and Recreation. We provide customized vehicle solutions for applications including: essential needs (ambulances, fire apparatus, school buses, mobility vans and municipal transit buses), industrial and commercial (terminal trucks, cut-away buses and street sweepers) and consumer leisure (recreational vehicles (“RVs”) and luxury buses). Our brand portfolio consists of 27 well-established principal vehicle brands including many of the most recognizable names within our served markets. Several of our brands pioneered their specialty vehicle product categories and date back more than 50 years. Investors-REVG
News Article | May 16, 2017
Advanced HVAC is celebrating their 10th anniversary of business success in Ottawa. Founded as a modest, family-owned business, Advanced HVAC has more than doubled in size over the past decade, continuing to experience growth and success through a dedication to premium craftsmanship and client satisfaction. “Over the past 10 years, our company philosophy has remained the same. As a family-owned and operated business, we have strong community values that guide every interaction with our customers,” said David Laplante, Owner, Advanced HVAC. “We offer exceptional service for our clients because we care. This includes our 24-hour emergency response service, 365 days a year, and some of the best product and service warranties on the market.” Advanced HVAC offers a full spectrum of professional services in heating and cooling, including installation, repair, and maintenance services for your furnace, air conditioner, and water heater. Advanced HVAC also offers air purifier installation for the home to ensure you and your family are experiencing the cleanest, healthiest air possible. “Premium air quality and HVAC energy-efficiency have become increasingly dominant concerns for homeowners across Ottawa in recent years. Using the latest HVAC products and technologies, we ensure your home is running effectively and efficiently, positively impacting your monthly utility bill and your health,” said David Laplante. “We provide customized solutions for each homeowner, identifying the best products and systems to suit your home and your budget.” Each HVAC technician on the Advanced HVAC team is highly qualified, fully licensed, trained and specialized in all aspects of the trade. Advanced HVAC is registered and quality assessed with the Technical Standards and Safety Authority (TSSA). Advanced HVAC is also A+ accredited with the Better Business Bureau (BBB), BAXI certified and members of HRAI and OCA. Advanced HVAC services the Ottawa area, including Orleans, Nepean, Rockland, Navan, Embrun, Russell, Limoges, Casselman, Manotick, and Kanata. To get a quote on Ottawa HVAC services, contact Advanced HVAC today. Advanced HVAC is a medium-sized family-operated heating and cooling company serving the Ottawa and surrounding areas. Advanced HVAC offers a variety of products backed by the best warranties in the industry. They provide fast and efficient 24-hour emergency HVAC service in Ottawa, 365 days of the year. The company has over 100 years of combined HVAC experience. One of their detail-oriented, dedicated, and talented heating and cooling technicians is ready to assist you today.
News Article | May 15, 2017
NES Financial, a Silicon Valley FinTech company providing technology-enabled solutions for efficient back and middle office administration of complex financial transactions, recently added senior executives Eric Weinstein and Chet Hayman to its sales organization. Both will report to Senior Vice President of Sales, Christian Lyndes. Weinstein joins the Company from Conifer Financial Services where he was Director of Development, Fund Services. His prior experience includes Vice President of Business Development and Marketing at Vastardis Capital Services. Weinstein will be based in New York City. Hayman joins the Company from Satuit Technologies, where he was Senior Vice President of Sales. His prior experience includes senior roles in sales and finance at Oracle Corporation, First Union Securities, and UBS. Hayman will be based in the Boston area, working out of the Company’s Rockland, MA office. “With our unique solutions and the rapid growth we are seeing in private equity, it was incumbent upon us to tap executives like Eric and Chet that blend technology sales and financial services expertise,” said Lyndes. “Their backgrounds and experience fit right in with our company and will immediately be valuable additions to the Sales team.” On what set NES Financial apart from other service providers, Weinstein said, “NES Financial is uniquely positioned to meet the needs of today’s private equity fund managers and investors with a next-generation third-party fund administration solution.” Added Hayman, “The combination of Silicon Valley technology prowess and Big Four accounting acumen sets NES Financial apart from other firms in the private equity fund administration space.” The Company’s innovative Private Equity Administration Solution provides a fully integrated, scalable, and cost-effective technology platform for third-party fund administration. Designed to help private equity firms raise capital faster, the solution reduces operational risk by improving compliance and data security, creating greater transparency and service to limited partners, and using data analytics to generate valuable business intelligence for general partners. About NES Financial NES Financial is a Silicon Valley financial technology (FinTech) company providing technology-enabled solutions and services for the efficient back and middle office administration of complex financial transactions. Serving private equity, commercial real estate, and Fortune 1000 clientele, we offer industry-leading fund administration, loan servicing, specialized EB-5 administration, and 1031 tax deferred exchange services. Our unwavering commitment to data security, operational redundancy, and compliance reporting is evidenced by 11 consecutive years of successful independent audits of our technology, processes, and financial controls. Today, NES Financial services over 190 funds, administers over $75B of 1031 transactions annually, and has worked with over 550 EB-5 projects. For more information, visit NES Financial.
Rockland, Inc. | Date: 2017-06-28
An electro-magnetic induction fluid conductivity sensor is described which includes a hollow non-conductive body defining a fluid chamber. The fluid chamber has a first end and a second end. A voltage transformer is provided which is capable of inducing an electric field into fluid positioned within the fluid chamber, thereby causing an electric current to flow through the fluid. An instrument is provide for measuring the electric current. A conductive shunt receives the electric current induced by the voltage transformer in the liquid at the first end of the sample chamber and returning the electric current to the second end to complete an electrical circuit.
Rockland, Inc. | Date: 2014-06-26
Recombinant B. burgdorferi proteins, representative of the life cycle, are membrane-immobilized to capture antibodies in biological samples. Lateral flow technology incorporating gold colloid deposition results in band visualization indicative of a positive test.
Rockland, Inc. | Date: 2014-11-07
A member formed of a set of elongated corrugated cardboard plies secured together with a biodegradable adhesive along the lengths thereof and coated with a biodegradable coating which may be stacked to form a support for a portion of an elongated weighty member.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 225.00K | Year: 2014
DESCRIPTION (provided by applicant): Post-transcriptional RNA modification plays an important role in biological processes. For example, adenosines to nosiness or A-to-I editing are most abundant in the central nervous system (CNS) and essential for normalCNS development. Presently, the available reagents for detection, quantitation, or immunoprecipitation of modified RNA are extremely limited. Rockland Immunochemicals is collaborating with Aptagen to develop synthetic antibodies for detection and quantitation of modified RNAs. In Phase I, as a proof-of-principle, high-affinity and target-specific aptamers and aptamer-based detection assays for inosine and N6- methyladenosine containing RNA will be developed. In Phase II, aptamer reagents and assays to morethan 60 RNA modifications known in eukrayotes will be developed. These affinity reagents will be used in microarrays to profile RNA modifications in different mouse CNS disorder models. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 249.97K | Year: 2013
Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop novel imaging agents that can be used in both cancer diagnosis and targeted therapy. In this phase I proposal, high-affinity camelid single domain antibodies to three cancer biomarkers HER2, EGFR and mesothelin will be developed. The antibodies will be directionally conjugated to near-infrared spectrum fluorescentdyes. Properties of the nanobody, including in vivo clearance, rapid tumor accumulation, in vivo stability and bioavailability, will be investigated in tumor xenograft animal models. In the Phase II, selected antibodies will be conjugated with chelators for radiolabeling with metal radionuclides. Pharmacokinetic, pharmacodynamics, immunogenic and toxicological characteristics of agents will be investigated in animal models to obtain data necessary for filing an Investigational New Drug application. PUBLIC HEALTH RELEVANCE
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 149.87K | Year: 2011
The RON and c-MET signal pathways are critical regulators of cell growth, survival, migration, differentiation, and drug resistance. High levels of activated RON or c-MET have been observed in a number of human cancers. Activation of RON and c-MET by phosphorylation initiates a signal transduction cascade that promotes cancer cell proliferation, invasiveness, apoptotic and drug resistance, and metastasis. A number of anticancer drugs currently in clinical trials are targeting both of of these pathways. Further, the activation state and protein levels of RON and c-MET are good indicators of drug treatment efficacy and cancer cell survival outcome. In Phase I, we will develop a quantitative immunoassay to monitor the phosphorylation state of either RON or GAB1(the target of c-MET) in various activated and unactivated cancer cell lines. The ELISA kit will be manufactured and written SOPs created. In Phase II, we will use the RON or GAB1 kit to measure activation and protein levels in clinical samples from a wide range of cancers and additional PD assays, including studies using drugs that upregulate or downregulate these targets. The availability of RON and GAB1 detection kits will aid clinicians and researchers to monitor these proteins in a number of diseasesand predict the efficacy of cancer treatment.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 999.00K | Year: 2011
In response to this NCI solicitation, Rockland proposes to develop a novel method to assay the pharmacodynamic (PO) properties of anti-cancer small molecules targeting the PI3K/mTOR/AKT signaling pathway by quantitatively and independently measuring the phosphorylation of each unique AKT isoform in a validated multiplex immunoassay. The developed PD-AKT-ELISA would offer improved personalized medicine, whereby physicians would prescribe a dosage according to the pharmacodynamic effects of anti-cancer drugson individual patients, or modify therapeutic modality based on the feedback for each individual Akt isoform. We plan to use a number of anti-cancer drug candidates in this study and to produce reagents, including monoclonal antibodies to measure inactiveand active AKT isoforms suitable for a fit-for-use theranostic quantitative biomarker ELISA for AKT. The PO-AKT-ELISA and associated reagents will be produced, optimized, validated and applied to both solid tumor and soft tumor xenograft tissue. The reagents and validated assay will measure all AKT isoforms in its active and inactive states to fill a need not currently addressed by products or technologies commercially available to researchers and clinicians. The end result will be a multiplex assay thatcan be used by most existing immunoassay readers in both a research and high through-put clinical environment. Assay results will allow physicians to more precisely target dosages or types of drugs that modulate the PI3K/mTOR/AKT pathway, and will ultimately lower treatment costs by more accurately prescribing effective doses of anticancer drugs and potentially shortening the duration of drug treatment regimens.